- Report
- January 2024
- 200 Pages
Global
From €3730EUR$4,150USD£3,271GBP
- Report
- November 2023
- 630 Pages
Global
From €6831EUR$7,600USD£5,991GBP
€8539EUR$9,500USD£7,488GBP
- Report
- April 2023
- 120 Pages
Global
From €4269EUR$4,750USD£3,744GBP
- Report
- April 2023
- 110 Pages
Global
From €4269EUR$4,750USD£3,744GBP
- Report
- May 2024
- 183 Pages
Global
From €4045EUR$4,500USD£3,547GBP
- Report
- August 2024
- 185 Pages
Global
From €4045EUR$4,500USD£3,547GBP
- Clinical Trials
- November 2024
- 450 Pages
Global
From €3595EUR$4,000USD£3,153GBP
€4494EUR$5,000USD£3,941GBP
- Report
- August 2024
- 200 Pages
Global
From €3478EUR$3,869USD£3,050GBP
- Report
- December 2023
- 212 Pages
Global
€4490EUR$4,995USD£3,937GBP
- Report
- November 2025
Global
From €450EUR$536USD£408GBP
- Report
- January 2024
- 168 Pages
Global
€4490EUR$4,995USD£3,937GBP
- Book
- September 2024
North America

Melanoma is a type of cancer that affects the skin and is the most serious form of skin cancer. It is caused by the uncontrolled growth of pigment-producing cells, known as melanocytes. Melanoma is the fifth most common cancer in the United States, with an estimated 87,110 new cases in 2020. It is also the leading cause of death from skin disease.
The melanoma market within the oncology space is a rapidly growing segment, driven by the increasing prevalence of the disease and the development of new treatments. The market is expected to be driven by the increasing adoption of targeted therapies, immunotherapies, and combination therapies. Additionally, the increasing focus on personalized medicine and the development of novel drug delivery systems are expected to drive the market.
Some of the key players in the melanoma market include Bristol-Myers Squibb, Merck & Co., Novartis, Roche, Pfizer, and Eli Lilly. Show Less Read more